# Raltegravir-Model
Whole-body PBPK model of Raltegravir.

**The latest release of this model including a report on model building, model features and model evaluation can be found [here](https://github.com/Open-Systems-Pharmacology/Raltegravir-Model/releases/tag/v1.0).**

<p align="center">
  <img src="Raltegravir.png">
</p>


## Code of conduct

Everyone interacting in the Open Systems Pharmacology community  (codebases, issue trackers, chat rooms, mailing lists etc...) is  expected to follow the Open Systems Pharmacology [code of conduct](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODE_OF_CONDUCT.md#contributor-covenant-code-of-conduct).

## Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the [contribution guidelines](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CONTRIBUTING.md#ways-to-contribute). If you are contributing code, please be familiar with the [coding standard](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODING_STANDARDS.md#visual-studio-settings).

## License

The model code is distributed under the [GPLv2 License](https://github.com/Open-Systems-Pharmacology/Suite/blob/develop/LICENSE).
